MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer's disease

G Jedlitschky; S Vogelgesang; H K Kroemer

doi:10.1038/clpt.2010.126

MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer's disease

Clin Pharmacol Ther. 2010 Oct;88(4):441-3. doi: 10.1038/clpt.2010.126.

Authors

G Jedlitschky¹, S Vogelgesang, H K Kroemer

Affiliation

¹ Department of Pharmacology, Center of Pharmacology and Experimental Therapeutics, Ernst-Moritz-Arndt University, Greifswald, Germany.

PMID: 20856238
DOI: 10.1038/clpt.2010.126

Abstract

The accumulation of neurotoxic amyloid-β (Aβ) peptides within the brain represents a hallmark of Alzheimer's disease (AD). It is proposed to be partly due to reduced elimination of Aβ from the brain into the blood. Diverse mechanisms of Aβ clearance out of the brain have been suggested. As discussed here, several lines of evidence suggest a significant role of the MDR1-P-glycoprotein (ABCB1), which is a major component of the blood-brain barrier (BBB).

MeSH terms

ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1 / physiology*
ATP-Binding Cassette Transporters / metabolism
Alzheimer Disease / metabolism*
Amyloid beta-Peptides / metabolism*
Animals
Blood-Brain Barrier / metabolism*
Brain / metabolism
Humans
Peptide Fragments / metabolism*

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1
ATP-Binding Cassette Transporters
Amyloid beta-Peptides
Peptide Fragments